Navigation Links
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Date:9/3/2014

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain ris
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
2. Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
3. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
6. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
7. DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
8. CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years
9. Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytrens Cords At ASSH Annual Meeting
10. TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
11. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... LONDON , September 4, 2015 ... HCM) today announces that Hutchison MediPharma Limited ("HMP"), ... endpoint in the second proof-of-concept ("POC") trial of ... lung cancer ("NSCLC") in China ... clearly succeeded in meeting the primary efficacy endpoint ...
(Date:9/3/2015)... -- Report Details Ovarian Cancer Therapies ... and Emerging Opportunities What,s the future for treating ... forecasts those pharmaceutical revenues. There you find outlooks ... explore trends, results, treatments, R&D, and opportunities, seeing ... to 2025 at overall world market, submarket, product ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... – Your New Guide to that Market, its R&D and ... want to assess the future of cancer-treating medicines? Visiongain,s new ... helping you stay ahead. There you discover financial data, R&D ... In our analysis you see forecasted sales ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Jan. 30 Tigris Pharmaceuticals,Inc., a privately held ... ascending dose clinical study of aminoflavone,pro-drug (AFP-464) for ... dosed,in December 2007 and enrollment is ongoing., ... determine the dose limiting,toxicity (DLT) and maximum tolerated ...
... Product Urokinase and Evaluates Strategic ... Development Program, TUCSON, Ariz. Jan. 30 ImaRx ... will emphasize growing the,market for urokinase in contrast to ... additional value-creating opportunities for,urokinase was made possible by the ...
Cached Medicine Technology:Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors 2Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors 3ImaRx Therapeutics Transitions Business Strategy 2ImaRx Therapeutics Transitions Business Strategy 3ImaRx Therapeutics Transitions Business Strategy 4ImaRx Therapeutics Transitions Business Strategy 5
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Residence in South Glastonbury, Connecticut, has been selected for the Residential Award of ... energy efficiency and resiliency measures. Chosen from a highly competitive field of submissions, ...
(Date:9/4/2015)... Charlotte, NC (PRWEB) , ... September 04, 2015 ... ... water filtration products, has a Labor Day offer that cannot be passed up. ... to stock up on necessary air and water filtration product replacements. Take advantage ...
(Date:9/3/2015)... , ... September 04, 2015 , ... AlignLife of ... September. , "There are so many children and adults who don't have the ... Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those in ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... motor disease, , WEDNESDAY, March 10 (HealthDay News) -- ... smoke and Parkinson,s disease, researchers have found that smoking ... but smoking a large number of cigarettes a day ... had suggested that smokers have a lower risk of ...
... technological revolution, the "light fantastic" continues to impact people,s ... and performing intricate surgery. As the golden anniversary of ... 7th, Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ... exciting future of this amazing invention. C&EN ...
... ... HBS Alumnus Recognized for PrescriptionDrugs.com Business Plan , ... Boston, MA (PRWEB) March 11, 2010 -- A week ... their first ever HBS Alumni New Venture Contest . PrescriptionDrugs.com co-founder Mike “Zappy” ...
... A clinical research trial of a new treatment to ... safety stage, according to the UC Irvine neurologist who led ... no ill effects after the sequential administration of growth factors ... brain. All new drug treatments must pass this safety stage ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Longtime Smokers May Find Protection From Parkinson's 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 2Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 3Health News:New Consumer Era Places Retailers at the Forefront of Participating in Shoppers' Health 4Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 2Health News:Visionworks(R) Provides Eye Care For Pittsburgh's Smiling Irish Eyes 3
... The Classic is a ... designed for use by people ... the easy-to-use picture control selector, ... materials in high-contrast black text ...
... magnifier (model CLCM) was designed especially for ... to see objects at a distance as well ... camera design allows viewing at near, intermediate and ... between near and distant viewing. With its included ...
... Maxport is a powerful magnifier that helps the partially ... of a hand magnifier attached to a pair of ... is no need for a TV set. The display ... images on a book, a can of food, a ...
... electronic magnification system. It was designed with ... patient in mind. PVA contains many new ... you to see your face to shave ... pixel full color camera. It connects easily ...
Medicine Products: